This study details the first robust nonlinear mixed-effects modelling (NONMEM®)-based model to predict the pharmacokinetics of a standard dosage of intravenous immunoglobulin in patients with Guillain–Barré syndrome.

Disease severity and additional treatment with methylprednisolone are important covariates increasing the clearance of high-dose intravenous immunoglobulin.

This model provides a tool to explore intravenous immunoglobulin trial designs and potentially optimise the treatment of individual patients with Guillain–Barré syndrome and/or other diseases treated with high-dose intravenous immunoglobulin.